|
FR2435905A1
(fr)
*
|
1978-09-13 |
1980-04-11 |
Anvar |
Nouveaux agents molluscicides derives du benzamido-2 nitro-5 thiazole
|
|
US4315018A
(en)
*
|
1978-12-07 |
1982-02-09 |
Rossignol Jean F |
Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
|
|
JPS5697278A
(en)
*
|
1979-12-21 |
1981-08-05 |
Wellcome Found |
Heterocyclic compound
|
|
US5578621A
(en)
*
|
1994-09-08 |
1996-11-26 |
Romark Lab Lc |
Benzamide derivatives
|
|
US5387598A
(en)
*
|
1994-04-13 |
1995-02-07 |
Rossignol; Jean-Francois |
Composition and galenic formulation suitable for combatting affections of the lower abdomen
|
|
ES2161201T3
(es)
*
|
1994-04-13 |
2002-12-01 |
Romark Lab Lc |
Derivados de benzamida, composiciones que contienen dichos derivados ysu empleo.
|
|
US5859038A
(en)
*
|
1994-09-08 |
1999-01-12 |
Romark Laboratories, L.C. |
Method for treatment of helicobacter pylori infections
|
|
MX9604483A
(es)
*
|
1994-09-08 |
1998-02-28 |
Jean-Francois Rossignol |
Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
|
|
US5968961A
(en)
*
|
1997-05-07 |
1999-10-19 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
|
AU756451B2
(en)
*
|
1997-05-07 |
2003-01-16 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
|
DE69827417T2
(de)
*
|
1997-05-07 |
2005-10-27 |
Romark Laboratories, L.C., Tampa |
Tizoxanide und/oder Nitazoxanide enthaltende pharmazeutische Zubereitungen
|
|
US5935591A
(en)
*
|
1998-01-15 |
1999-08-10 |
Romark Laboratories, L.C. |
Method for treatment of equine protozoal myeloencephalitis with thiazolides
|
|
US5925622A
(en)
*
|
1998-07-13 |
1999-07-20 |
Romark Laboratories, L.C. |
Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
|
|
SE0102764D0
(sv)
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
|
US7125568B2
(en)
|
2001-08-23 |
2006-10-24 |
Sung Michael T |
Lipophilic drug compositions
|
|
GB0226930D0
(en)
|
2002-11-19 |
2002-12-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0325402D0
(en)
*
|
2003-10-31 |
2003-12-03 |
Astrazeneca Ab |
Compounds
|
|
GB0327761D0
(en)
*
|
2003-11-29 |
2003-12-31 |
Astrazeneca Ab |
Compounds
|
|
GB0328178D0
(en)
*
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Compounds
|
|
BRPI0507746A
(pt)
*
|
2004-02-18 |
2007-07-10 |
Astrazeneca Ab |
composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
|
|
CA2554686A1
(fr)
*
|
2004-02-18 |
2005-09-01 |
Astrazeneca Ab |
Composes
|
|
TW200600086A
(en)
*
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
|
UA90864C2
(en)
|
2004-09-09 |
2010-06-10 |
Ромарк Лебораториз, Л.К. |
Halogenated benzamide derivatives
|
|
US20060194853A1
(en)
*
|
2004-10-08 |
2006-08-31 |
Rossignol Jean F |
Alkyl benzamides
|
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
|
WO2006040527A1
(fr)
|
2004-10-16 |
2006-04-20 |
Astrazeneca Ab |
Procede de fabrication de composes de phenoxy benzamide
|
|
GB0423044D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
|
US20070015803A1
(en)
*
|
2005-04-12 |
2007-01-18 |
Romark Laboratories L.C. |
Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
|
|
US20110059941A1
(en)
*
|
2005-05-24 |
2011-03-10 |
Peter William Rodney Caulkett |
2-phenyl substituted imidazol [4,5b] pyridine/pyrazine and purine derivatives as glucokinase modulators
|
|
TW200714597A
(en)
*
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
|
EP2027113A1
(fr)
*
|
2005-07-09 |
2009-02-25 |
AstraZeneca AB |
Dérivés d'hétéroaryl benzamide utilisés en tant qu'activateurs de la glk dans le traitement du diabète
|
|
NZ564608A
(en)
*
|
2005-07-09 |
2009-09-25 |
Astrazeneca Ab |
Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
|
|
US20110053910A1
(en)
*
|
2005-07-09 |
2011-03-03 |
Mckerrecher Darren |
2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes
|
|
US9202182B2
(en)
*
|
2005-08-11 |
2015-12-01 |
International Business Machines Corporation |
Method and system for analyzing business architecture
|
|
TW200738621A
(en)
*
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
|
AP2907A
(en)
*
|
2006-01-09 |
2014-05-31 |
Romark Lab Lc |
Viral hepatitis treatment
|
|
WO2008008480A2
(fr)
*
|
2006-07-12 |
2008-01-17 |
Cumbre Pharmaceuticals Inc. |
Dérivés de rifamycine contenant du nitrohétéroaryl
|
|
CN100465169C
(zh)
*
|
2006-08-02 |
2009-03-04 |
杭州欣阳三友精细化工有限公司 |
硝唑尼特的制备方法
|
|
TW200825063A
(en)
*
|
2006-10-23 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
|
SA07280576B1
(ar)
*
|
2006-10-26 |
2011-06-22 |
استرازينيكا ايه بي |
مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
|
|
BRPI0721143A2
(pt)
*
|
2006-12-21 |
2014-03-11 |
Astrazeneca Ab |
Forma cristalina do composto processo para a formação da mesma, uso de um composto, método para tratar doenças mediadas por ativador de glicocinase
|
|
CN101007792B
(zh)
*
|
2007-01-31 |
2010-05-26 |
浙江大学 |
一种合成硝基噻唑苯酰胺化合物的方法
|
|
US8124632B2
(en)
*
|
2007-08-03 |
2012-02-28 |
Romark Laboratories, L.C. |
Alkylsulfonyl-substituted thiazolide compounds
|
|
MX2011001333A
(es)
*
|
2008-08-04 |
2011-03-15 |
Astrazeneca Ab |
Derivados de pirazolo [3, 4] pirimidin-4-ilo y sus usos para tratar la diabetes y obesidad.
|
|
AU2009333559B2
(en)
|
2008-12-09 |
2015-03-12 |
Gilead Sciences, Inc. |
Modulators of toll-like receptors
|
|
GB0902406D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Crystalline polymorphic form
|
|
GB0902434D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Chemical process
|
|
BRPI1007945C8
(pt)
|
2009-02-13 |
2021-05-25 |
Romark Laboratories Lc |
formulação farmacêutica de liberação controlada de nitazoxanida, tizoxanida ou uma combinação dos mesmos, e, comprimido de bicamada para administração oral
|
|
WO2010116176A1
(fr)
*
|
2009-04-09 |
2010-10-14 |
Astrazeneca Ab |
Dérivé de pyrazolo [4, 5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité
|
|
WO2010116177A1
(fr)
|
2009-04-09 |
2010-10-14 |
Astrazeneca Ab |
Dérivé de pyrazolo [4,5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité
|
|
EP3078377A3
(fr)
*
|
2009-05-12 |
2017-04-05 |
Romark Laboratories, L.C. |
Nitazoxanide et tizoxanide en tant qu'agents antiviraux
|
|
MX341877B
(es)
|
2009-06-26 |
2016-09-06 |
Romark Laboratories L C * |
Compuestos y métodos para tratar influenza.
|
|
CN101602744B
(zh)
*
|
2009-06-30 |
2011-06-01 |
青岛康地恩药业有限公司 |
一种硝唑尼特的制备方法
|
|
MX340846B
(es)
|
2012-01-27 |
2016-07-28 |
Rhein Siegfried Sa De Cv |
Composición de nitazoxanida mejorada y proceso para prepararla.
|
|
US20150250765A1
(en)
|
2012-09-27 |
2015-09-10 |
Siegfried Rhein S.A. De C.V. |
Nitazoxanide and mebendazole synergic composition, processes for the preparation thereof, and use of said composition for the treatment of human parasitosis
|
|
EP3010345A4
(fr)
*
|
2013-06-21 |
2017-04-12 |
The Regents of The University of California |
Potentiel thérapeutique étendu dans des antimicrobiens à nitrohétéroaryle
|
|
TWI733652B
(zh)
|
2014-07-11 |
2021-07-21 |
美商基利科學股份有限公司 |
用於治療HIV之toll樣受體調節劑
|
|
JP2017526730A
(ja)
|
2014-09-16 |
2017-09-14 |
ギリアード サイエンシーズ, インコーポレイテッド |
Toll様受容体モジュレーターの固体形態
|
|
CN107105660A
(zh)
|
2014-11-11 |
2017-08-29 |
罗马克实验室有限公司 |
使用替唑尼特、其类似物或盐的前药的治疗组合物和治疗方法
|
|
CN105175352A
(zh)
*
|
2015-10-27 |
2015-12-23 |
杭州澳医保灵药业有限公司 |
一种硝唑尼特的制备方法
|
|
CN106831640A
(zh)
*
|
2015-12-03 |
2017-06-13 |
江苏正大丰海制药有限公司 |
一种硝唑尼特晶体的制备方法
|
|
HK1250945A1
(zh)
|
2016-03-31 |
2019-01-18 |
罗马克实验室有限公司 |
用於治疗病毒性感染的噻唑化物化合物
|
|
PT3442580T
(pt)
|
2016-04-11 |
2020-12-23 |
Genfit |
Métodos de tratamento para doenças colestáticas e fibróticas
|
|
CA3046158A1
(fr)
|
2017-01-27 |
2018-08-02 |
Genfit |
Compositions pharmaceutiques pour polytherapie
|
|
WO2018195035A1
(fr)
|
2017-04-18 |
2018-10-25 |
Romark Laboratories L.C. |
Inhibition de la protéine disulfure-isomérase a3
|
|
WO2019241376A1
(fr)
|
2018-06-14 |
2019-12-19 |
The Trustees Of Columbia University In The City Of New York |
Traitement de troubles cognitifs à l'aide de nitazoxanide (ntz), d'analogues de nitazoxanide (ntz) et de leurs métabolites
|
|
JP2022528727A
(ja)
|
2019-04-12 |
2022-06-15 |
ジェンフィット |
酸化ストレスに関連する疾患の治療に使用するためのニタゾキサニド及びチアゾリド
|
|
KR20220011685A
(ko)
|
2019-05-22 |
2022-01-28 |
길리애드 사이언시즈, 인코포레이티드 |
Tlr7 조절 화합물과 hiv 백신의 조합
|
|
CN114630660A
(zh)
|
2019-10-28 |
2022-06-14 |
基恩菲特公司 |
具有抗氧化特性的联合疗法
|
|
EP4182304A1
(fr)
|
2020-07-20 |
2023-05-24 |
Romark Laboratories, L.C. |
Sels cristallins de tizoxanide et de 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) avec de l'éthanolamine, de la morpholine, de la propanolamine, de la pipérazine et de la n-méthylpipérazine
|
|
AU2021333566A1
(en)
|
2020-08-24 |
2023-03-16 |
Romark Laboratories L.C. |
Use of thiazolides against coronaviruses
|
|
CN114044761B
(zh)
*
|
2021-02-24 |
2022-05-17 |
成都贝诺科成生物科技有限公司 |
一种新的硝基噻唑衍生物及其应用
|
|
WO2022218239A1
(fr)
*
|
2021-04-12 |
2022-10-20 |
杜心赟 |
Nouveau composé de thiazole, son procédé de préparation et son utilisation
|
|
CA3233848A1
(fr)
|
2021-10-05 |
2023-04-13 |
Sasidhar Balappa SOMAPPA |
Procede ameliore pour preparer du nitazoxanide et de ses intermediaires
|
|
CN116898846B
(zh)
*
|
2022-04-12 |
2025-10-24 |
成都贝诺科成生物科技有限公司 |
一种硝基噻唑衍生物在制备抑制幽门螺杆菌的抑菌剂中的用途
|